[Corrigendum] Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF­7 and MDA­MB­231 breast carcinoma cells.

Subsequently to the publication of this paper, the authors have realized that the name of the fifth listed author, Theresa Vilsmaier, was spelt incorrectly (it appeared as "Vilsmeier" in print). The corrected author list, as it shown have appeared in the paper, is shown above. The authors regret that the name of the fifth author on the paper was spelt incorrectly, and apologize to the readers for any inconvenience caused. [The original article was published in Oncology Reports 41: 387-396, 2019; DOI: 10.3892/or.2018.6789].

Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF­7 and MDA-MB-231 breast carcinoma cells.

We investigated the anticarcinogenic potential of green tea and its components epigallocatechin gallate (EGCG) and quercetin, as well as tamoxifen, on MCF-7 and MDA-MB-23 breast cancer cells. Using high-performance liquid chromatography, the quantity of EGCG and quercetin in green tea was analyzed. The receptor status of the cells was confirmed immunohistochemically. Various viability and cytotoxicity tests were later performed to investigate the effects of the substances. After incubating the cells with green tea extract, EGCG, quercetin and tamoxifen, a decrease in viability (MTT test) or proliferation (BrdU assay) was found in all cell tests with varying effects, depending on the assay used. The effects were similar in both cell lines. This work confirmed that EGCG and quercetin are contained in green tea and that both substances in pure form and as green tea have an anticarcinogenic effect on both estrogen receptor-positive and -negative breast cancer cells. This effect could also be demonstrated with tamoxifen in both cell lines (MTT and BrdU assays). These results suggest that the effects observed in these experiments are not generated only via estrogen receptor-mediated pathways.

Immunohistochemical studies of mucinous mammary carcinomas and their metastases.

In cancer cells the expression of mucins is variable in amount and cellular localization. Alteration in glycosylation occurs and leads to the appearance of novel structures. The aim of this study was to investigate the expression of epitopes known as CA19-9, CA50, CA242, MUC1, MUC1-Core and Thomsen-Friedenreich (TF) in mucinous carcinomas. The formalin-fixed and paraffin-embedded tissue samples of the breast (n=29) and their metastases in axillary lymph nodes (n=6) were analysed using immunohistochemical methods. The mucinous breast tumours expressed MUC1, MUC1-Core and TF, while CA19-9, CA50 and CA242 showed a negative staining reaction. The examined metastases showed similar expression patterns as the corresponding primary tumours. In the case of an unknown metastatic primary tumour, such immunohistochemical analysis in axillary lymph nodes might be helpful. A positive reaction of CA19-9, CA50 and CA242 might suggest the presence of a gastrointestinal tumour, especially a pancreatic carcinoma, whereas positive findings of MUC1, MUC1-Core and TF could indicate the presence of a mucinous mammary carcinoma.